
Thermo Fisher Scientific RORB Monoclonal Antibody (OTI1B6), TrueMAB
RORB 단백질을 표적하는 Mouse monoclonal 항체로, Western blot에 적합합니다. Human 시료에 반응하며, 고순도의 Affinity chromatography로 정제되었습니다. PBS/BSA/glycerol buffer에 보관되며, 연구용으로만 사용 가능합니다.
- 카탈로그번호
- TA806861
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific RORB Monoclonal Antibody (OTI1B6), TrueMAB
Applications
- Western Blot (WB): 1:2,000 dilution tested
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Clone | OTI1B6 |
| Immunogen | Human recombinant protein fragment corresponding to amino acids 1–260 of human RORB produced in E. coli |
| Conjugate | Unconjugated |
| Form | Liquid |
| Concentration | 1 mg/mL |
| Purification | Affinity chromatography |
| Storage Buffer | PBS with 1% BSA, 50% glycerol |
| Contains | 0.02% sodium azide |
| Storage Conditions | −20°C, Avoid Freeze/Thaw Cycles |
| Shipping Conditions | Ambient (domestic); Wet ice (international) |
Target Information
Retinoid-related orphan receptor beta (RORβ), a NR1 thyroid hormone receptor, influences the development and functioning of the central nervous system, including sensory input integration and circadian timing. Disruption of RORβ in mice results in juvenile ataxia, retinal degeneration, circadian activity abnormalities, and delayed onset of male fertility. RORβ binds to monomeric response elements containing the sequence AnnTAGGTCA as a monomer.
An alternatively spliced isoform, RORβ2, has been identified in rats, with expression confined to the pineal gland and retina. RORβ2 shares common DNA- and putative ligand-binding domains with wild-type RORβ but has a distinct amino-terminal domain. RORβ expression has been observed in various regions of the mouse brain.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Thermo Fisher Scientific 상품 둘러보기
전체보기문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.
